AbbVie has announced its plan to acquire Nimble Therapeutics, a developer of oral peptides, for $200 million. This acquisition will strengthen AbbVie's drug development pipeline, particularly in the autoimmune disease sector.
Nimble Therapeutics, previously part of Roche, has a unique platform for peptide synthesis that has the potential to lead to innovative therapeutic solutions. They are currently working on three drug candidates, including an oral peptide designed to inhibit C5, which is associated with severe autoimmune conditions. They are also developing candidates for psoriasis and inflammatory bowel disease.
The acquisition of Nimble Therapeutics will provide AbbVie with access to these promising drug candidates and their advanced peptide synthesis technology. This aligns with AbbVie's strategic goals and reflects the industry trend of established companies seeking to enhance their capabilities through targeted acquisitions.
This acquisition positions AbbVie to make a significant impact in the treatment of autoimmune diseases and could lead to further growth and innovation in the biopharma industry.